Engineered Probiotic Fights Cancer Cachexia by Producing Therapeutic Ketone
Modified Lactobacillus produces 3-hydroxybutyrate to combat muscle wasting and tumor growth in colon cancer cachexia.
Summary
Researchers engineered Lactobacillus rhamnosus to produce 3-hydroxybutyrate, creating a dual-action therapy for colon cancer cachexia. In mouse studies, this modified probiotic improved survival, reduced tumor progression, and prevented muscle wasting. The engineered strain restored healthy gut bacteria, increased beneficial short-chain fatty acids, and reduced inflammation. This approach combines the metabolic benefits of ketone production with probiotic gut health effects, offering a promising new treatment for cancer-related muscle wasting.
Detailed Summary
Cancer cachexia, characterized by severe muscle wasting and metabolic dysfunction, affects up to 80% of advanced cancer patients and significantly worsens outcomes. This study addresses a critical unmet need by engineering a probiotic solution that tackles multiple aspects of the condition simultaneously.
Researchers genetically modified Lactobacillus rhamnosus GG to produce 3-hydroxybutyrate (3-HB), a ketone body with known therapeutic properties. They tested this engineered strain (LGGK) in a mouse model of colon cancer cachexia, measuring survival, tumor growth, muscle mass, gut microbiome changes, and inflammatory markers.
The results were striking: LGGK supplementation significantly improved survival rates, slowed tumor progression, and prevented muscle wasting compared to controls. The engineered probiotic restored gut microbial diversity, increased beneficial bacteria populations, and boosted short-chain fatty acid production while reducing harmful microbes. Additionally, LGGK demonstrated potent anti-inflammatory effects, reducing elevated cytokines in both blood and skeletal muscle.
This dual-action approach represents a significant advancement in cancer supportive care. By combining 3-HB's metabolic benefits with probiotics' gut-modulating properties, LGGK addresses cachexia's complex pathophysiology through multiple mechanisms. The strategy could potentially extend to other metabolic and inflammatory disorders, highlighting engineered probiotics' therapeutic potential.
Key Findings
- Engineered L. rhamnosus producing 3-hydroxybutyrate improved survival in cancer cachexia mice
- LGGK supplementation reduced tumor progression and prevented muscle wasting
- Treatment restored gut microbial diversity and increased beneficial bacteria
- Anti-inflammatory effects reduced pro-inflammatory cytokines in serum and muscle
- Dual-action approach combines ketone metabolism with probiotic gut benefits
Methodology
Study used genetically engineered Lactobacillus rhamnosus GG modified to produce 3-hydroxybutyrate. Researchers tested the strain in a murine colon cancer cachexia model, measuring survival, tumor progression, muscle mass, gut microbiome composition, and inflammatory markers.
Study Limitations
Study conducted only in mouse models; human trials needed to confirm safety and efficacy. Long-term effects of engineered probiotic consumption unknown. Limited to abstract-only information restricts detailed methodology and statistical analysis review.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.